Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1858]
News [2849]
Articles [215]
Editorials [1]
Conferences [142]
elearning [13]
‘Fiery’ cell death during bladder cancer treatment may trigger chemo resistance by fueling cancer stem cells
‘Fiery’ cell death during bladder cancer treatment may trigger chemo resistance by fueling cancer stem cells
ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells
ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer...
Study presents a breakthrough in overcoming drug resistance in cancer – hope for treating intractable diseases like diabetes​
Study presents a breakthrough in overcoming drug resistance in cancer – hope for treating intractable diseases...
Study sheds light on why some prostate tumours are resistant to treatment
Study sheds light on why some prostate tumours are resistant to treatment
New precision medicine approach identifies a promising ovarian cancer treatment
New precision medicine approach identifies a promising ovarian cancer treatment
New insights on genetic damage of some chemotherapies could guide future treatments with less harmful side effects
New insights on genetic damage of some chemotherapies could guide future treatments with less harmful side effects
Antibody-cancer drug combo shows promise against aggressive lymphoma
Antibody-cancer drug combo shows promise against aggressive lymphoma
Bioengineered tumour model offers new tool in fight against peritoneal cancers
Bioengineered tumour model offers new tool in fight against peritoneal cancers
Precision oncology Organ Chip platform accurately and actionably predicts chemotherapy responses of patients suffering from oesophageal adenocarcinoma
Precision oncology Organ Chip platform accurately and actionably predicts chemotherapy responses of patients...
FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma
FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation